AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Morbilliform Eruptions in Patients on Immunotherapy

Description

The presentation discusses morbilliform eruptions in patients undergoing immunotherapy, highlighting the increasing use of these treatments in cancer therapy. Dermatologists play a crucial role in managing skin-related immune adverse events, as over 50% of patients on immunotherapy experience such effects. The mechanisms of these eruptions are explored, particularly the activation of cytotoxic T cells which may unintentionally target normal cells. A commonly noted condition is the maculopapular rash, which typically emerges three to six weeks after therapy begins, characterized by erythematous macules and papules often found on the trunk and extremities. Diagnosing this condition relies on clinical presentation and can involve skin biopsies to distinguish it from other dermatitis types. Management strategies vary with the severity of the rash, informed by grading systems that assess body surface area involvement. Appropriate treatment may include topical medications and careful use of oral steroids to minimize treatment interruptions. The presentation also touches on more severe reactions like Stevens-Johnson syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), noting that careful monitoring is essential for these patients. Case studies illustrate the complexities involved in diagnosis and treatment, underscoring the importance of individualized care plans for patients experiencing skin toxicities from immunotherapy.

View more

Conclusions

  • Immunotherapy has significantly increased over the years, impacting a large number of cancer patients who are now eligible for treatment.
  • More than 50% of patients undergoing immunotherapy will experience cutaneous immune-related adverse events.
  • Active involvement of dermatologists can lead to fewer treatment interruptions and decreased reliance on systemic steroids for patients on immunotherapy.
  • Maculopapular rash is the most common skin-related adverse effect associated with immunotherapy, commonly occurring 3-6 weeks after treatment starts.
  • The diagnosis of cutaneous adverse reactions often relies on clinical observation, but histological evaluation can provide essential information for management.
  • Various cutaneous immune-related adverse events may present similarly, necessitating differentiation through biopsies in certain cases.
  • Management of maculopapular rashes should follow established grading criteria to guide treatment approaches and dose adjustments of immunotherapy.
  • More severe reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis have been linked to immune checkpoint inhibitors, with significant mortality rates indicating a serious concern.
  • The pathogenesis of severe reactions may involve concurrent medication exposures, suggesting a need for thorough medication review in cases of severe skin reactions.
  • Patients may continue immunotherapy with careful management of skin reactions, allowing for sustained cancer treatment while addressing dermatological issues.
  • Li T, Wang X, Niu M, Wang M, Zhou J, Wu K, Yi M. Bispecific antibody targeting TGF-ß and PD-L1 for synergistic cancer immunotherapy. Front Immunol. 2023 Jul 13;14:1196970.
  • Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020;82(4):994-996.
  • Handa S et al. Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol. 2020 Sep 3;12:1756287220951404.
  • Li, H.; Sahu, K.K.; Maughan, B.L. Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. Cancers 2022, 14, 2460.
  • Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268.
  • Zhu J, Chen G, He Z, Zheng Y, Gao S, Li J, Ling Y, Yu X, Qiu K, Wu J. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021 Jun 10;37:100951.
  • Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. J Am Acad Dermatol. 2020 Nov;83(5):1475-1477.
  • Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017 Apr;44(4):381-384.